OCEL1 Inhibitors
OCEL1 inhibitors represent a class of chemical compounds designed to specifically target and modulate the activity of the OCEL1 protein, a member of the oculocerebrorenal protein family. OCEL1, also known as "oculocerebrorenal syndrome protein-like 1," plays an essential role in various cellular processes such as protein trafficking, signaling, and intracellular transport. Inhibitors of OCEL1 are synthesized or isolated with the intention of binding to specific active or allosteric sites on the protein, thereby interfering with its normal function. These inhibitors typically function by disrupting the interaction between OCEL1 and other biomolecules that are critical for its role in cellular homeostasis. Such interactions often involve the formation of multi-protein complexes, and the inhibition of OCEL1 can lead to the disassembly of these complexes, causing a shift in cellular signaling cascades or metabolic pathways.
Chemically, OCEL1 inhibitors are characterized by their high specificity for the target protein, often achieved through complex molecular docking mechanisms. These compounds are designed to exploit the structural features of the OCEL1 protein, such as hydrophobic pockets or key amino acid residues, to achieve binding. Structural analysis techniques like X-ray crystallography and NMR spectroscopy are frequently employed to understand the binding mechanisms and optimize the potency and selectivity of these inhibitors. Furthermore, synthetic modifications, such as the addition of functional groups or optimization of stereochemistry, are common in order to fine-tune the bioavailability, stability, and binding efficiency of OCEL1 inhibitors in a controlled chemical environment. These precise interactions are key to understanding how OCEL1 inhibitors can modify biochemical pathways at a molecular level.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that prevents the activation of the PI3K/Akt pathway. OCEL1 can be indirectly inhibited by this compound if it relies on PI3K for membrane localization or is part of a signaling cascade that is initiated by PI3K activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, which would lead to a downstream reduction in Akt phosphorylation and activity. If OCEL1's activity is mediated through Akt-dependent signaling, inhibition by LY294002 would reduce OCEL1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of cell growth and metabolism. If OCEL1 plays a role in processes governed by mTOR signaling, then its inhibition by rapamycin would lead to decreased OCEL1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor, which leads to decreased ERK activation. If OCEL1 functions downstream of the MEK/ERK pathway, then PD98059 would lead to a reduction in OCEL1 activity by inhibiting this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 also inhibits MEK, preventing ERK activation. OCEL1, if it operates downstream of the MEK/ERK signaling axis, would have its activity diminished in the presence of U0126. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP Kinase. If OCEL1 is activated as part of the cell's response to stress that involves p38 MAPK signaling, then SB203580 would inhibit OCEL1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is involved in stress, inflammatory response, and apoptosis. OCEL1's activity could be indirectly reduced if it is part of the JNK signaling pathway, by the use of SP600125. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that affects NF-κB activation. If OCEL1 is regulated by NF-κB signaling, bortezomib could reduce OCEL1 activity by inhibiting proteasomal degradation of IκB, thus preventing NF-κB translocation to the nucleus. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 also inhibits the proteasome, leading to the accumulation of polyubiquitinated proteins. If the degradation of such proteins is necessary for OCEL1 activation, MG132 would lead to an inhibition of OCEL1 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits SERCA, disrupting calcium homeostasis. If OCEL1's function is calcium-dependent or part of calcium-regulated signaling pathways, then thapsigargin would lead to the inhibition of OCEL1 activity. | ||||||